Research advances toward more effective, long-lasting and side effect-free cancer treatments
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 03:16 ET (22-Jun-2026 07:16 GMT/UTC)
Researchers from Trinity College Dublin, Dublin City University and University College Dublin will use newly awarded funding of €670,000 from Enterprise Ireland’s Commercialisation Fund to develop a breakthrough blood-based screening test for bowel cancer (colorectal cancer, CRC).
The team, working with clinicians at St. Vincent’s University Hospital, seeks to transform cancer outcomes by moving screening away from invasive or unpleasant methods to their simple, high-accuracy blood test, named “CASPDx CRC”.
The CASPDx team is now initiating the formal validation of their product. Patients are being recruited in all Bowel Screen Centres in the HSE Dublin & South East region as part of clinical validation studies, with assistance of the UCD Clinical Research Centre. While the CASPDx CRC test is still at clinical validation and immunoassay development phases, the team aim to launch the test and spin-out as a company by the end of 2027.
A new consortium, bringing together more than 60 partners from 25 countries, has kicked off a five-year initiative to help improve the heart health of people living with and beyond cancer with a two-day meeting at St Thomas' Hospital and the London Institute for Healthcare Engineering.